Compare companies
Mainz Biomed N.V. | Gilead Sciences | Amgen | ||||
---|---|---|---|---|---|---|
Capitalization | ||||||
Price | 4.27 | 107.89 | 306.86 | |||
Price priv. | ||||||
Number of shares, million | 16.24 | 1258 | 538 | |||
Capitalization, billion | 0 | 94.55 | 140.05 | |||
EBITDA, billion | -0.0247 | 7.61 | 7.9 | |||
EV, billion | 0.0198 | 119.11 | 206.55 | |||
Profit and loss report | ||||||
Net profit, billion | -0.0263 | 5.67 | 6.72 | |||
Revenue, billion | 0.000895 | 27.12 | 28.19 | |||
EPS | -1.62 | 4.5 | 12.49 | |||
Balance | ||||||
Assets, billion | 0.0154 | 62.13 | 97.15 | |||
Debt, billion | 0.0063 | 24.99 | 64.61 | |||
Balance cost, billion | 0.0032 | 22.75 | 6.23 | |||
Cash, billion | 0.0071 | 6.09 | 10.94 | |||
Coefficients | ||||||
Dividend yield, % | 0 | 3.69 | 2.92 | |||
Dividend | 0 | 3.87 | 9.13 | |||
Dividend yield priv., % | 0 | 0 | 0 | |||
Dividend priv. | 0 | 0 | 0 | |||
Dividends/profit, % | 0 | 67.24 | 67.83 | |||
P/S | 21.77 | 3.7 | 5.42 | |||
P/BV | 6 | 4.41 | 24.53 | |||
P/E | 0 | 17.69 | 22.76 | |||
Ev/Ebitda | -0.8043 | 15.66 | 26.16 | |||
Debt/Ebitda | -0.2536 | 3.29 | 8.18 | |||
Efficiency | ||||||
ROE | -809.29 | 24.9 | 107.78 | |||
ROA | -170.65 | 9.12 | 6.91 | |||
ROIC | 0 | 11.06 | 17 | |||
Ebitda margin | -2754.77 | 28.05 | 28.01 | |||
Net margin | -2936.5 | 20.89 | 23.83 | |||
Momentum | ||||||
1 week, price changes | -21.83 % | +0.3535 % | -2.82 % | |||
1 month, price changes | -36.97 % | -2.83 % | -0.9234 % | |||
3 months, price changes | -22.17 % | +14.84 % | +16.02 % | |||
6 months, price changes | +1 343.55 % | +29.93 % | -3.84 % | |||
1 year, price changes | +247.57 % | +47.77 % | +7.18 % | |||
3 years, price changes | -76.12 % | +81.82 % | +31.59 % | |||
5 years, price changes | +80.42 % | +33.46 % | ||||
10 years, price changes | +24.66 % | +101.52 % |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription